Denali Therapeutics Inc (DNLI)
24.22
-0.20
(-0.82%)
USD |
NASDAQ |
Nov 21, 16:00
24.95
+0.73
(+3.01%)
After-Hours: 07:44
Denali Therapeutics Total Liabilities (Quarterly): 135.52M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 135.52M |
| June 30, 2024 | 115.51M |
| March 31, 2024 | 125.62M |
| December 31, 2023 | 122.96M |
| September 30, 2023 | 118.45M |
| June 30, 2023 | 118.91M |
| March 31, 2023 | 442.64M |
| December 31, 2022 | 417.81M |
| September 30, 2022 | 416.30M |
| June 30, 2022 | 408.01M |
| March 31, 2022 | 402.93M |
| December 31, 2021 | 441.87M |
| September 30, 2021 | 437.69M |
| June 30, 2021 | 437.11M |
| March 31, 2021 | 442.50M |
| Date | Value |
|---|---|
| December 31, 2020 | 453.75M |
| September 30, 2020 | 187.76M |
| June 30, 2020 | 145.17M |
| March 31, 2020 | 150.55M |
| December 31, 2019 | 158.34M |
| September 30, 2019 | 164.78M |
| June 30, 2019 | 162.43M |
| March 31, 2019 | 159.95M |
| December 31, 2018 | 115.14M |
| September 30, 2018 | 83.30M |
| June 30, 2018 | 81.78M |
| March 31, 2018 | 74.92M |
| December 31, 2017 | 20.92M |
| September 30, 2017 | 17.17M |
| December 31, 2016 | 365.22M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
115.51M
Minimum
Jun 2024
453.75M
Maximum
Dec 2020
283.97M
Average
295.34M
Median
Total Liabilities (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 10.68M |
| Perspective Therapeutics Inc | 62.68M |
| Protalix BioTherapeutics Inc | 29.13M |
| Electromed Inc | 7.427M |
| Armata Pharmaceuticals Inc | 149.21M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.454B |
| Shareholders Equity (Quarterly) | 1.318B |